Idexx laboratories announces third quarter results

Achieves third quarter revenue growth of 4% reported and 8% organic, driven by cag diagnostics recurring revenue growth of 5% reported and 9% organic, building on high prior year growth continued strong demand for diagnostic services and excellent commercial execution support record third quarter premium instrument placements, driving 14% growth in global premium instrument installed base delivers eps of $2.15, an increase of 6% as reported and 13% on a comparable basis supported by operating margin expansion of 120 basis points as reported and 100 basis points on a comparable basis adjusts 2022 revenue guidance to 3.5% - 4.5% growth as reported and 6.5% - 7.5% organic. at midpoint, reflects consistent reported revenue outlook as solid organic growth trends offset updated foreign exchange impacts updated eps outlook of $7.74 - $7.98 reflects consistent operational outlook at midpoint, supported by strong second half comparable operating profit gains, and incorporates $0.05 combined impact from updated foreign currency exchange rate and interest rate projections westbrook, maine , nov. 1, 2022 /prnewswire/ -- idexx laboratories, inc. (nasdaq: idxx), a global leader in pet healthcare innovation, today announced third quarter results and an update on u.s. companion animal diagnostics trends.
IDXX Ratings Summary
IDXX Quant Ranking